AMOXICILLIN MLABS amoxicillin (as trihydrate) 250 mg/5 mL powder for oral suspension bottle pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amoxicillin mlabs amoxicillin (as trihydrate) 250 mg/5 ml powder for oral suspension bottle pack

micro labs pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

AMOXICILLIN MLABS amoxicillin (as  trihydrate) 125 mg/5 mL powder for oral suspension bottle pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amoxicillin mlabs amoxicillin (as trihydrate) 125 mg/5 ml powder for oral suspension bottle pack

micro labs pty ltd - amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; sodium benzoate; saccharin sodium; disodium edetate; xanthan gum; silicon dioxide; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli,respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli,genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: [trade name] may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

AMOXIL amoxicillin 1g (as sodium) powder for injection vial Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amoxil amoxicillin 1g (as sodium) powder for injection vial

aspen pharmacare australia pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g) - injection, powder for - excipient ingredients: - amoxil parenteral is intended for use where the patient's condition precludes the administration of the oral form. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia: (bacterial) h. influenzae; e. coli (see microbiology); p.mirabilis; streptococcus; s. pneumoniae; s. faecalis and salmonella typhi. skin and skin structure: staphylococcus, non-penicillinase-producing; streptococcus; e. coli (see microbiology). respiratory, acute and chronic: haemophilus influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. co

Ibiamox Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

ibiamox

douglas pharmaceuticals limited - amoxicillin sodium 1000mg;   - powder for injection - 1000 mg - active: amoxicillin sodium 1000mg   - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.